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Oxidative stressSince its discovery, the unique properties of the naturally occurring amino acid, L-ergothioneine (EGT; 2-
mercaptohistidine trimethylbetaine), have intrigued researchers for more than a century. This widely distrib-
uted thione is only known to be synthesized by non-yeast fungi, mycobacteria and cyanobacteria but accu-
mulates in higher organisms at up to millimolar levels via an organic cation transporter (OCTN1). The
physiological role of EGT has yet to be established. Numerous in vitro assays have demonstrated the antiox-
idant and cytoprotective capabilities of EGT against a wide range of cellular stressors, but an antioxidant role
has yet to be fully veriﬁed in vivo. Nevertheless the accumulation, tissue distribution and scavenging proper-
ties, all highlight the potential for EGT to function as a physiological antioxidant. This article reviews our cur-
rent state of knowledge. This article is part of a Special Issue entitled: Antioxidants and Antioxidant
Treatment in Disease.; GPx, glutathione peroxidase;
e oxygen species; TNF, tumor
kin (1β, 6, 8); RA, rheumatoid
ants and Antioxidant Treatment
02, 21 Lower Kent Ridge Road,
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In 1909, Charles Tanret, whilst investigating the ergot fungus,
Claviceps purpurea, which devastated rye grain, isolated a unique
crystalline sulfur-containing compound, later identiﬁed as a tri-
methylbetaine of 2-thiol-L-histidine [1]. This water soluble thiol,
named ergothioneine (EGT) after the ergot fungus, is known to be
synthesized only by non-yeast fungi, certain bacteria belonging to
the order Actinomycetales and recently also by cyanobacteria [2–4].
Yet despite the inability to be synthesized by higher animals, EGT was
soon identiﬁed in the blood of pigs by two independent groups, Hunter
et al. and Benedict et al., as a confounder of uric acid measurements
[5,6]. Since then there have been hundreds of reports on EGT regarding
its synthesis, abundance in nature, chemical properties, possible physi-
ological functions and potential role as an antioxidant. Many reports
have shown that EGT may act as a cytoprotectant in vitro, but its role
in vivo is uncertain. This review aims to shed light on the unique
properties of EGT and evaluate the evidence for its potential roles
in vivo.1.1. Properties of ergothioneine
In solution, EGT exists as a tautomer between its thiol and thione
forms (Fig. 1), however at physiological pH it exists predominantly as
the thione. Hence EGT only reacts with some sulfhydryl reagents such
as iodoacetamide, but not with DTNB (5,5′-dithiobis-(2-nitrobenzoic
acid)) [7,8]. Another unique attribute of EGT is that the standard
redox potential of the thiol–disulﬁde couple is −0.06 V in contrast
to other naturally occurring thiols which typically range between
−0.2 and −0.32 V [9]. In combination, these two properties confer
greater stability under physiological conditions, hence EGT does not
readily undergo auto-oxidation as rapidly as other ‘antioxidant’ thiols
such as glutathione (GSH) which can generate free radicals in the
process [10]. For example, the oxidation and generation of H2O2
were observed by a wide range of thiols in cell culture media, where-
as no signiﬁcant decrease in EGT was observed following incubation
in cell culture media [11] for 4 days at room temperature (unpub-
lished). This stability also accounts for EGT's slow degradation and re-
sistance to disulﬁde formation [12,13]. Formation of the EGT disulﬁde
has been demonstrated at very low pH in the presence of copper or
H2O2, but not in neutral or alkaline solutions [14].
1.2. Chemistry and synthesis
EGT is a colorless, odorless compound of relative molecular mass
229.30 and a relatively high solubility in aqueous solutions (aqueous sol-
ubility limit of 0.9 M at 25 °C). Naturally occurring EGT possesses the L
conﬁguration around the α carbon with optical rotation of [α]D +116°
[15]. The biosynthesis of EGT proceeds from L-histidine through
the intermediary precursor hercynine and then to EGT through
the incorporation of sulfur derived from cysteine, as determined
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in this conversion are still not known. Early attempts to synthesize
EGT chemically resulted in racemization of the product [19]. The
synthesis of enantiomerically pure L-(+)-EGT was ﬁrst described
by Xu and Yadan [20].2. Uptake and distribution
2.1. Abundance in foods and tissues
Despite apparently being exclusively synthesized in fungi, cyano-
bacteria and mycobacteria (no evidence to date exists for the direct
biosynthesis of EGT in animals and higher plants), EGT is ubiquitous-
ly present in most cells and tissues of plants and mammals [13]. A
wide array of foods contain trace amounts of EGT, however some
foodswere found to possess particularly high levels including certain
species of mushrooms (where it can be synthesized), black and red
beans, red meat, liver, kidney, and grains [21].
In humans, EGT has been shown to accumulate in various cells and
tissues at high concentrations (100 μM to 2 mM), most abundantly in
erythrocytes, bone marrow, liver, kidney, seminal ﬂuid and the lens
and cornea of eyes [22–25]. Early on it was recognized that EGT was
obtained through dietary means. For example, grain-fed pigs showed
very high levels of EGT in blood whereas pigs fed on a puriﬁed casein
diet had no detectable EGT [26]. Furthermore, synthetic [35S]-EGT fed
to rats was observed to enter blood and tissues [27]. Metabolic turnover
rate for EGT was also shown to be relatively slow with no appreciable
drop in blood and liver levels seen in rats fasted for 1 week [12]. Likewise,
this unique pharmacokinetic property of EGT was observed in mice
which maintained blood levels of 3H-EGT for more than 14 days follow-
ing a single oral administration [28]. This high accumulation and slow
turnover of EGT have been attributed in part to the renal reabsorption
and low urinary excretion of 3H-EGT [28].
An earlier study revealed gender differences in blood EGT ac-
cumulation, likely associated with testosterone levels, since male
and female rats injected with testosterone revealed EGT levels
double that of untreated females [29]. However these results
have yet to be replicated. A study in humans found that blood
EGT levels increase to 1.5–2.0 mg/100 ml from 1 to 10 years of
age (y/o) peaking at around 3.7 mg/100 ml by 18 y/o and gradual-
ly declining to 2.3–3.0 mg/100 ml between 19 and 50 y/o and pla-
teauing beyond 51+y/o with an average of 2.8 mg/100 ml [30].
Interestingly, similar age-related declines have been observed in
the total activity of the antioxidant enzyme, glutathione peroxi-
dase (GPx) [31,32].
However even though EGT has a relatively wide tissue distribu-
tion it is not currently considered an essential dietary component
and there are no reports of symptoms due to its deﬁciency. Like-
wise, rats fed on an EGT-depleted diet did not reveal any obvious
physiological changes, nor were there any abnormalities in repro-
duction, delivery and growth rate of the second generation animals
[22,33].Fig. 1. Structure of thione–thiol tautomers of EGT (2-mercaptohistidine trimethylbetaine).
the thiol (b) hence conferring greater stability over other simple thiols such as GSH.2.2. Analysis of ergothioneine
Since its discovery, the methods employed to quantify EGT in
biological samples have constantly evolved to increase speciﬁcity
and sensitivity. Many earlier methods harnessed chemical assays
and colorimetric techniques to isolate and identify EGT from
blood [34–38]. However these techniques lacked speciﬁcity and
hence often gave erroneously high values of EGT in blood [13].
Mayumi et al. [12] ﬁrst harnessed liquid chromatography to ana-
lyze EGT in rat blood and tissue and later Dubost and colleagues
[39] applied liquid chromatography-mass spectroscopy for the
quantiﬁcation of EGT in mushrooms. The lack of speciﬁcity and
sensitivity of certain earlier analytical methods as highlighted in
Table 1, may raise doubts as to the reliability of these early esti-
mates of EGT in animal and plant material, therefore such measure-
ments will probably need to be veriﬁed using current techniques.
Furthermore, a portion of tissue EGT has been found to be associat-
ed with proteins, hence previous reports may be inaccurate due to
exclusion of protein-bound EGT [33]. This highlights the need for
standardized and calibrated, chemically robust, methods to accu-
rately analyze EGT.
2.3. Ergothioneine transport
Even though EGT is present in many cells, plasmamembranes seem
to be intrinsically impermeable to EGT and hence a mechanism for
uptake and accumulation in cells must exist [27]. Furthermore, cellular
uptake of EGT exhibits signiﬁcant temperature and Na+-dependence
and is saturable, further supporting involvement of carrier-mediated
transport [40]. The gene SLC22A4 encodes an integral membrane
protein, the organic cation transporter (OCTN1) that facilitates
pH-dependent transport of speciﬁc compounds across the membrane.
Unlike OCTN2, which is predominantly involved in carnitine transport,
OCTN1 has poor carnitine translocation activity, suggesting there is like-
ly to be another physiological role for the transport [41]. In comparison
to OCTN2, little is known about the physiological role of OCTN1. Recently
however, Grundemann et al. identiﬁed that EGT is a key substrate for
OCTN1 using a liquid chromatography mass spectrometry difference
shading approach [42]. The speciﬁcity of OCTN1was further demonstrat-
ed by the lack of discernible uptake of various organic cations including a
130 and 25-fold lower transport, relative to EGT, of structurally similar,
methimazole and hercynine, respectively [43]. While uptake of EGT is
both Na+ and pH dependent, transport is only lost at unphysiologically
low Na+ and pH [44,45].
Silencing the gene encoding the OCTN1 in cell cultures inhibits uptake
of EGT [46]. Similarly, metabolomic analysis of OCTN1 knockout
(octn1−/−) mice revealed that most tissues of the animal were almost
completely deﬁcient of EGT, indicating an absence of alternative mecha-
nisms of uptake [28]. Analysis of various tissues in the body (Fig. 2)
revealed a high level of OCTN1 in the bone marrow, which is consistent
with high levels of EGT reported in erythrocytes [43]. Likewise intestinal
tissue and peripheral blood cell concentrations of EGT are relatively inde-
pendent of diet but closely correlated toOCTN1mRNAexpression [44,47].In solution at physiological pH, EGT exists predominantly in the thione (a) rather than
Table 1
The following table details the concentration of EGT in human and rat blood and selected rat tissues as determined by different analytical methods in the past. The considerable
variation in the observed concentrations highlights the critical need to apply modern analytical techniques to standardize concentrations of EGT in biological samples. Earlier col-
orimetric methods lacked speciﬁcity due to extraneous compounds and many modiﬁcations focused on removing impurities. These methods also lacked sensitivity and some may
not have considered protein bound EGT. Current analytical techniques such as liquid chromatography–mass spectrometry have yet to be applied to human and animal tissues. ND—
not detectable.
Sample [EGT]
(mg/a100 ml or b100 g)
Method Authors Ref.
Human erythrocytesa 1.25–4.0 Chemical assay (daizo method) Hunter, 1928 [34]
7.5 Chemical assay (silver precipitation) Behre and Benedict, 1929 [148]
1.9–5.5 Chemical assay (daizo method–strong alkali) Latner, 1948 [149]
5.4–5.7 Chemical assay (daizo method–lead acetate) Hunter, 1949 [36]
2.0–3.1 Chemical assay (daizo method–iodobismuthous
acid precipitation)
Lawson et al., 1950 [150]
7.3 Chemical assay (bromine water) Touster, 1951 [151]
9.6 Chemical assay (daizo method–iodobismuthous
acid precipitation)
Fraser, 1951 [152]
1.8–4.2 Chemical assay (daizo–ion exchange) Melville, 1953 [37]
1.0–2.6 Chemical assay (trimethylamine estimation) Jocelyn et al., 1958 [38]
1.1–3.2 Chemical assay (2,2′-dipyridyl disulﬁde) Carlsson et al., 1974 [153]
3.2 Cation exchange chromatography Fahey et al., 1981 [154]
Rat erythrocytesa 5.3 Chemical assay (daizo method) Beatty, 1952 [138]
4.1 Chemical assay (daizo method) Mellville, 1954 [22]
1.6 Chemical (p-chloromercuribenzoate (PCMB)
method)
Hama et al., 1972 [155]
0.28 High performance liquid chromatography Mayumi et al., 1978 [12]
0.21 Thin-layer chromatography Kaneko et al., 1980 [116]
0.67 High performance liquid chromatography Muda et al., (1988) [156]
Rat liverb 13.3 Chemical assay (daizo method) Mellville, 1954 [22]
4.7 Chemical (PCMB method) Hama et al., 1972 [155]
4.83 High performance liquid chromatography Mayumi et al., 1978 [12]
7.82 Thin-layer chromatography Kaneko et al., 1980 [116]
Rat kidneyb 4.3 Chemical assay (daizo method) Mellville, 1954 [22]
6.73 Chemical (PCMB method) Hama et al., 1972 [155]
1.87 High performance liquid chromatography Mayumi et al., 1978 [12]
1.58 Thin-layer chromatography Kaneko et al., 1980 [116]
Rat testicleb ND Chemical assay (daizo method) Mellville, 1954 [22]
0.24 High performance liquid chromatography Mayumi et al., 1978 [12]
0.5 Thin-layer chromatography Kaneko et al., 1980 [116]
Rat brainb ND Chemical assay (daizo method) Mellville, 1954 [22]
0.21 High performance liquid chromatography Mayumi et al., 1978 [12]
0.41 Thin-layer chromatography Kaneko et al., 1980 [116]
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3.1. Antioxidant properties
Numerous rationales have been proposed to explain the ubiqui-
tous presence of EGT and its extensive uptake and accumulation in
tissues [48]. These include a role for EGT as a cation chelator [49–
52], factor in bioenergetics [53], regulator of gene expression [48]
and immune regulator [54,55]. However the most often cited attri-
bute of EGT is its possible function as an antioxidant and cytopro-
tectant [56–60]. A wide body of evidence suggests that EGT may
function as a physiological antioxidant. Closer examination of the
distribution of EGT in the body reveals that the compound is prefer-
entially accumulated in organs, cells and secretions predisposed to
high levels of oxidative stress and inﬂammation such as liver, kid-
neys, erythrocytes, eye lens and seminal ﬂuid [22,23,25]. In addi-
tion, depleting HeLa cells of EGT through OCTN1 silencing, leads to
increases in oxidative burden on mitochondrial components, visu-
alized through increased protein carbonylation (a general biomark-
er of oxidative damage to proteins [61]) and mitochondrial DNA
damage (measured by quantitative real-time PCR of D-Loop muta-
tions), further emphasizing the possible roles as a physiological an-
tioxidant [46]. Analysis of OCTN1 knockout mice developed by Kato
and coworkers, revealed that the animals which were completely
deﬁcient in EGT, appeared to be more susceptible to oxidative stress
as determined by signiﬁcantly higher lethality in octn1−/−mice fol-
lowing intestinal ischemia and reperfusion injury [28] which isknown to involve reactive oxygen species (ROS), relative to wild-
type mice [62]. However, no other biomarkers of oxidative damage
were reported by the authors.
EGT has been established in vitro as a powerful scavenger of hydroxyl
radicals (•OH), hypochlorous acid (HOCl) and peroxynitrite (ONOO−)
[58,63–65]. EGT was also shown to deactivate singlet oxygen at a higher
rate (kΔ=2.3×107 M−1s−1) than other simple thiols including GSH
[66]. Indeed, the reactions of EGTwith •OH and peroxyl radicals were de-
termined by pulse radiolysis to have almost diffusion-controlled rate con-
stants of 1.2×1010 M−1 s−1 and 1.2×109 M−1 s−1, respectively [67].
These antioxidant abilities were demonstrated in more complex systems
through exposure ofα1-antiproteinase to HOCl and DNA to •OH generat-
ed by Cu2+ in the presence of H2O2 and ascorbate; EGT exerted almost
complete protection against damage in each case [58]. Hydroxyl radical
scavenging however, is unlikely to be a mechanism of antioxidant action
in vivo, since almost every biomolecule can react equally fast with •OH
and many are present at far greater levels than EGT [62,68].
Peroxynitrite (ONOO−), nitrosoperoxycarbonate (ONOOCO2−) and
carbonate radical are able to cause lipid peroxidation, damage protein
and DNA and deplete intracellular antioxidants and have been exten-
sively implicated in many disorders [69–71]. EGT was shown to be a
more effective scavenger of peroxynitrite than GSH and Trolox C
and dose-dependently prevented nitration of tyrosine and inactiva-
tion of α1-anti-proteinase at concentrations less than 1 mM [65,72].
EGT was also shown to dose-dependently protect PC12 cells from a
ONOO− generating system, 3-morpholinosydnonimine [73]. By com-
parison, direct reactivity of EGT with superoxide (•O2−) was found to
Fig. 2. Tissue expression of the EGT transporter, OCTN1, analyzed by real-time PCR
adapted from 2 independent sources (Grundemann et al. 2005; National Academy of
Sciences and Taubert et al. 2009; BMJ Journals) [42,47]. Data are relative to mRNA
level of the ileum for each set.
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103 M−1 s−1 [58]. EGT also had no effect on sodium nitroprusside
generated NO•-induced cell death, that is, its reaction with NO•, if
any, is also slow [73].
EGT was found to also have relatively poor direct reactivity with
H2O2 [57,74], although there have been some reports of its cytoprotec-
tive effects in cell cultures. In a human neuronal hybridoma cell line EGT
was shown to have mild protective effects against H2O2. Interestingly
however, it synergistically ampliﬁed the protective effects of N-acetyl-
cysteine, demonstrating dose-dependent inhibition of H2O2-induced
cell death [59]. Similarly, EGT protected PC12 cells from H2O2-inducedcytotoxicity and prevented DNA damage as observed by the comet
assay [75]. This protection was shown to involve inhibition of p38
MAPK and Akt activation; hence EGT may play a protective role in
H2O2-induced apoptosis by activation of intracellular antioxidant path-
ways involvingp38MAPK rather thanbydirect scavenging of H2O2 [75].
In vitro assays have also demonstrated that EGT can protect against DNA
damage and peroxidation of arachidonic acid by H2O2 and H2O2/heme
proteinmixtures, respectively [58,75]. The reduction of ferrylmyoglobin
(a reactive species formed when myoglobin reacts with H2O2) by EGT,
as demonstrated byArduini et al., [74]may be themechanismof protec-
tion of arachidonic acid and has been suggested to be the manner by
which EGT prevents ischemic myocardial damage [74].
Contradictory to many other studies, Ey et al. [21] found that EGT
only protected OCTN1 transfected HEK-293 against copper(II)-in-
duced toxicity, but not against a range of other cellular stressors as
opposed to GSH which protected against all stressors tested at equiv-
alent concentrations. Hence, together with the higher observable
levels of cellular GSH, they argued that EGT is not involved in the in-
tracellular antioxidant thiol defense system. These contrasting results
over previous observations of EGT's effectiveness against ROS were
suggested to be attributed to the earlier use of unphysiologically
high concentrations, use of cell free systems which differ from in
vivo and differing experimental conditions. Whilst these authors
used a model of perhaps limited physiological relevance, that is an
OCTN1 vector transfected HEK-293 cell line with modest EGT uptake
(whichmay differ greatly from high OCTN1 expressing cell types), the
results do indicate that GSH may still be the primary thiol defense in
cells.
3.2. Other evidence of antioxidant properties
Numerous other in vitro assays and data have also demonstrated
the potential antioxidant properties of EGT. Alloxan-induced lipid
peroxidation of phosphatidylcholine liposomes was inhibited by
67% and 100% with the addition of only 20 μM and 100 μM EGT, re-
spectively, which was double the protective effect of coenzyme Q10
[76]. Park et al. [77] investigated the free radical scavenging capacity
of rhizome extracts using the radical generators DPPH and ABTS, and
found that high radical scavenging values were correlated with the
EGT content of the extracts. ThemshAmutant ofMycobacterium smeg-
matis deﬁcient in mycothiol, a major intracellular detoxiﬁcation thiol
similar to GSH in eukaryotes, was found to overproduce ergothio-
neine, putatively as a compensatory function [78].
The in vitro antioxidant properties of EGT have been extended to
the commercial food industry, whereby it has demonstrated the abil-
ity to inhibit discoloration of red meats and ﬁsh and prevent lipid per-
oxidation and melanosic activity (melanin blackspot formation due to
the action of phenoloxidase) in preservation of post-harvest crusta-
ceans [79,80].
3.3. Chelation of metals
It was also discovered early on that EGT is able to chelate divalent
metal ions. Various groups have demonstrated the ability of EGT to
form complexes with divalent metal cations including Cu2+, Hg2+,
Zn2+, Cd2+, Co2+ Fe2+ and Ni2+ [49–51]. These complexes form at
a molar ratio of 2:1 of EGT to metal ion, with the most stable of
these being with copper, which has the highest complex formation
constant [50]. Binding of these metal ions in the body may help pre-
vent their participation in the generation of ROS. EGT was found to
protect both DNA and protein against copper-induced oxidative dam-
age (caused by Cu2+, H2O2 and ascorbate) through formation of a
redox-inactive EGT-Cu complex [52,58]. In animals and humans the
high levels of EGT in semen have been shown to prevent Cu2+ inhibi-
tion of sperm motility [81]. In contrast to the generation of ROS by
GSH in the presence of Cu2+ (via formation of a redox-active Cu(I)–
788 I.K. Cheah, B. Halliwell / Biochimica et Biophysica Acta 1822 (2012) 784–793[GSH]2 complex) [82], the complex of EGT with Cu2+ is relatively sta-
ble and hence does not decompose to generate radicals [52].
3.4. Intracellular ergothioneine
Kawano and colleagues [33] found that EGT accumulated in the
mitochondrial fraction of hepatic cells following injection of radiola-
belled EGT into rats. Consistent with this ﬁnding was the presence
of OCTN1 expression in the mitochondria in mammalian cell lines
[41]. This suggests that EGT may function to protect vulnerable mito-
chondrial DNA and other mitochondrial constituents from damage by
ROS generated by the electron transport chain. Supporting this theory
are the ﬁndings by Paul and Snyder [46], demonstrating increasedmi-
tochondrial DNA damage in response to OCTN1 silencing when cells
were exposed to H2O2. Furthermore the authors found that depleting
the cells of EGT also led to an increase in protein carbonyls, lipid per-
oxidation and susceptibility to H2O2-induced cell death [46].
Studies using fractionation of rat hepatic cells in a sucrose gradient
revealed very limited levels of EGT in the nucleus relative to the cyto-
plasm and mitochondria, however later studies by Markova et al.
revealed similar levels of EGT in the nucleus as the cytoplasm [83].
Regardless, the presence of EGT within the nuclear fraction suggests
OCTN1 mediated translocation across the nuclear membrane which
may indicate a possible role in protection of DNA. Although this pro-
tective ability has yet to be established, in vitro assays have demon-
strated that EGT is able to protect DNA from damage against various
reactive species [57,58].
4. Does ergothioneine function as an antioxidant in vivo?
Of course the literature is replete with examples of compounds
that exert excellent antioxidant properties in vitro but are ineffective
in vivo, such as many ﬂavonoids [62,84]. So is there evidence that EGT
could act in this way in vivo? A study by Deiana et al. [85] demonstrat-
ed the potential of EGT to decrease oxidative damage in vivo. Rats
supplemented with dietary EGT were found to have lower levels of
lipid peroxidation and higher levels of glutathione and α-tocopherol
in their liver and kidney, following administration of ferric-nitrilotria-
cetate, a catalyst of Fenton chemistry [85]. However this system im-
poses severe oxidative stress and the data do not indicate that EGT
acts as an antioxidant under normal circumstances.
4.1. Protection against UV and gamma radiation
The presence of OCTN1 has been reported in primary keratino-
cytes and ﬁbroblast cultures and also by immunohistochemical anal-
ysis of neonatal skin sections [76,83]. Although the functional role of
EGT in the skin is not known, its presence may suggest a role as a
physiological protectant against ultraviolet (UV)-induced ROS gener-
ation and damage. Much of the skin damage from UV radiation is me-
diated through the generation of ROS [86]. Several studies have
shown the cytoprotective effects of EGT against UV-induced damage
and cell death [76,87–89]. Keratinocytes exposed to UV radiation
showed a considerable decrease in cell viability along with a ﬁvefold
increase in caspase-9 activity, but addition of EGT was able to signif-
icantly increase cell viability and decrease caspase-9 activity [83,87].
Furthermore, EGT was shown to suppress the expression of tumor ne-
crosis factor-α (TNFα) and matrix metalloproteinase-1 resulting
from UV irradiation of ﬁbroblasts [90]. EGT is known to absorb light
in the UV range and hence this physical property may account for
some of its ability to block UV damage [91].
Motohashi et al. [92,93] demonstrated the radioprotective capa-
bilities of EGT. The γ-irradiation of metmyoglobin resulted in marked
structural changes, however the addition of 0.5 mM EGT was able to
prevent these changes [92]. Similarly, Hartman et al. [94] demonstrat-
ed that 1 mM EGT afforded complete protection against T4bacteriophage inactivation by γ-radiation. However, these results
may be through •OH scavenging in vitro, and so their physiological
relevance is uncertain.
4.2. Function of EGT in blood
Early studies failed to demonstrate uptake of EGT by mature
erythrocytes, however later studies by Mitsuyama and May [60]
clearly demonstrated uptake and accumulation beyond basal levels.
In addition, OCTN1 has been detected in mature erythrocytes [95].
The highly reactive ferryl-hemoglobin, derived from oxidation of
oxyhemoglobin, plays a critical role in lipid peroxidation in erythro-
cytes [62]. As previously mentioned EGT was able to reduce ferryl-
myoglobin/hemoglobin and also prevented the peroxidation of ara-
chidonic acid by a mixture of H2O2 and heme protein. Furthermore,
Spicer et al. [96] found that the rate of nitrite-induced oxidation of
hemoglobin in isolated rabbit blood, to methemoglobin, was in-
versely proportional to EGT content, and subsequent addition of
EGT reduced methemoglobin back to hemoglobin. Thus EGT may act
as a protectant against peroxidation in blood [58]. Correspondingly,
dietary intake of EGT was shown to retard nitrite-induced methemo-
globin formation in rabbits [96]. The ability of EGT to scavenge HOCl
[58], may also be relevant in protecting erythrocytes from damage by
neutrophils, the principal source of HOCl in the body [62].
Whilst the accumulation of EGT in erythrocytes is often suggested
to be due to the predisposition of red blood cells to oxidative burden
[62], it has been suggested that the expression of OCTN1 in bone mar-
row, fetal liver and erythroid cells may play a role in growth and dif-
ferentiation of erythrocytes [95,97]. In support of this notion,
Nakamura et al. [40] reported that depression of OCTN1 expression
by siRNA impaired the proliferation and differentiation of human leu-
kemic cell cultures. Further supporting a link between EGT and prolif-
eration, an up-regulation of OCTN1 has been found to occur not only
in fetal liver but also in regenerating liver tissue [98].
Additionally EGT has been suggested to play a role in glycolytic
metabolism by erythrocytes. Due to the lack of mitochondria in the
mature mammalian erythrocyte, energy is derived from the Emb-
den–Meyerhof pathway, resulting in lactate formation. Rats starved
for 24 h following EGT administration, maintained lactate levels in
their erythrocytes whereas levels in control animals dropped by 60%
[53]. Furthermore, when EGT was added directly to intact blood
cells in vitro, levels of lactate increased whilst levels of glucose-6-
phosphate and fructose-6-phosphate decreased relative to controls
[53]. Similarly, in vitro addition of EGT to human platelets incubated
with pyruvate-2-14C signiﬁcantly increased 14CO2 [99]. Whilst it is
difﬁcult to ascertain what these observations could mean it may sug-
gest there may be some interaction between EGT and the glycolytic
pathway.
4.3. Interaction with other intracellular defenses
Some researchers have suggested that EGT may interact with
other cellular stress defenses in times of excessive oxidative burden,
for example as a means to reduce oxidized GSH [74]. Kawano et al.
[100] whilst studying the inhibition of lipid peroxidation by EGT
using isolated mouse liver microsomes in vitro, observed a signiﬁcant
dose dependent increase in GPx, glutathione reductase and mito-
chondrial superoxide dismutase activities on addition of EGT. However
this response was seen at unphysiological concentrations, ranging
from 12.5 to 50 mM EGT. In mice, EGT was able to restore the cisplatin-
induced decrease in the GSH/GSSG ratio in the brain, suggesting that
that EGT may directly or indirectly assist in maintaining in vivo
thiol defenses [101]. In vitro studies have shown that oxidized EGT
can be reduced by either cysteine or GSH, however it is important
to note that this was achieved under conditions which probably
would not occur in vivo [14]. Arduini et al. [74] also spectrally
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H2O2/MbIII in vitro, with subsequent regeneration of EGT upon addi-
tion of GSH.
Despite the view that EGT may help maintain levels of GSH, this
would likely require enzymatic catalysis but there have been no reports
of any interaction between EGT and thioredoxin or glutaredoxins. Fur-
thermore, depletion of GSH by oxidative stressors did not affect levels
of EGT in erythrocytes, and conversely the auto-oxidation of GSH was
not accelerated in the presence of EGT [60]. A more recent study
found that EGT had no effect on glutathione transferases [102].
The oxidized formof EGT generated by pulse radiolysis, was demon-
strated to be rapidly reduced by ascorbic acid (k=6.3×108 M−1s−1)
similar to the regeneration of α-tocopherol in the body [67]. However,
this oxidized form of EGT has only been observed in vitro under condi-
tions probably not feasible in vivo, which raises doubts as to whether
these reactions are important in vivo.
5. Ergothioneine and disease
5.1. Chronic inﬂammatory conditions
The role of EGT in inﬂammation is somewhat controversial. On
the one hand mutations of the OCTN1 gene, SLC22A4 have been im-
plicated in chronic inﬂammatory conditions including rheumatoid
arthritis (RA) [103,104] and Crohn's disease (CD) [105,106]. Patients
with mildly active RA were found to have signiﬁcantly higher eryth-
rocytic and monocytic levels of EGT and these levels were closely
correlated to expression of OCTN1 mRNA in CD14+ cells [103].
Mice with collagen-induced arthritis also highly express OCTN1 in
hematological and immunological tissues of inﬂamed joints [104].
Similar to RA, analysis of the inﬂamed ileal mucosa of CD patients
also revealed elevated levels of EGT which corresponded to in-
creases in OCTN1 mRNA expression relative to non-CD subjects
[47]. Interestingly, the 503F variant of OCTN1 associated with CD
was found to have a 50% greater transport efﬁciency compared to
the normal variant (503L) [45]. Silencing OCTN1 expression in cul-
tured erythroid cells impairing EGT uptake, has been shown to be
pro-apoptotic [40]. Hence in these chronic inﬂammatory conditions,
the increased EGT has been postulated to stimulate inﬂammation by
promoting immune cell survival mediated by the anti-apoptotic
properties of EGT [45,47].
Some studies have indicated that the elevated levels of EGT may
be secondarily due to the cytokine-mediated up-regulation of
OCTN1. Incubation of Caco-2 cells with TNFα was shown to in-
crease OCTN1 expression through TNFα receptor-1 activation,
which would hence increase EGT and might in turn promote fur-
ther inﬂammation through the aforementioned prolonging of im-
mune cell survival [47]. Similarly OCTN1 expression was found to
be up-regulated by RA-associated inﬂammatory cytokines such as
interleukin-1β (IL), and by the transcription factor RUNX1 [107].
However whether this response is involved in pathogenesis or is
a counteractive response as a cellular defense, and the molecular
actions of EGT, are still undetermined.
Conversely a study undertaken by Kato et al. [28] in a cohort of
Japanese CD patients revealed that blood concentrations of EGT
were signiﬁcantly reduced relative to healthy volunteers. Kato et al.
likened their observations to OCTN1 knockout mice whereby animals
deﬁcient of EGT were predisposed to intestinal inﬂammation, hence
suggesting that EGT may play a role in counteracting intestinal in-
ﬂammation. In support of this anti-inﬂammatory effect, EGT has
been shown to inhibit the TNFα-mediated increase of IL-8 in epithe-
lial cell cultures [55]. Likewise EGT was shown to protect against free
fatty acid induced cell death through activation of p38 and JNK signal-
ing pathways and inhibition of IL-6 expression [54].
This presence of speciﬁc SLC22A4 mutations allegedly associat-
ed with CD or RA in speciﬁc populations, suggests the existence ofethnic differences in OCTN1 polymorphisms and the possibility of
differential disease susceptibility in speciﬁc populations. Indeed
numerous studies have identiﬁed that speciﬁc polymorphisms
linked to certain conditions may exist only in a particular ethnic
population [108–113]. Certain polymorphisms of SLC22A4 also
have a signiﬁcant impact on EGT uptake similar to the aforemen-
tioned 503F SLC22A4 [45]. Interestingly however, a study under-
taken by Petermann et al. [114] in subjects possessing the 503F
variant with increased susceptibility to CD, identiﬁed an associa-
tion between increased CD symptoms and the intake of EGT-rich
mushrooms. This may highlight a negative impact of excessive
EGT uptake, however, the exact role of EGT in chronic inﬂammato-
ry conditions and other disease has yet to be ascertained.
5.2. Potential effects against neurodegeneration
The expression of OCTN1 was detected in the brain of mice and
rats, albeit at lower levels than liver, kidney and intestinal tissue,
using RT-PCR [95,115]. Consistent with this are numerous reports of
EGT levels in mouse, rat, guinea pig, rabbit, cat, sheep and ox brain
of between 0.3 and 1 mg per 100 g brain tissue, indicating the capa-
bility of EGT to permeate the blood brain barrier [116–118]. Several
reports have demonstrated the cytoprotective effects of EGT in neuro-
nal cells against various oxidative challenges. The neurotoxic effects
of β-amyloid and cisplatin are well recognized and exposure of neu-
ronal cultures to either compound results in decreased cell viability
and apoptosis [119–122]. PC12 (rat pheochromocytoma) cells are
commonly used as a model for neurobiological studies, possessing
neuronal-like features such as neurite formation and terminal differ-
entiation in response to nerve growth factor. However, these cells are
not a true substitute for neurons [123]. Addition of EGT was shown to
dose-dependently rescue PC12 cells (which are known to express
OCTN1 [44]), from β-amyloid-induced apoptotic death as demon-
strated through decreases in TUNEL staining and pro-apoptotic Bax
and caspase 3 expression and a concomitant increase in PARP (nor-
mally cleaved by caspases) [73]. The effects of Aβ are believed to be
mediated through oxidative and nitrosative damage by •OH and
ONOO−, since pre-incubation of Aβ with EGT prior to addition to
cells had no signiﬁcant effect on the cytotoxicity of the peptide [73].
Similarly the neurotoxic effects of cisplatin are believed to be mediat-
ed via ROS generation, and treatment of PC12 cells with 0.1–10 μM
EGT prevented the antiproliferative effects of cisplatin and restored
neuritic outgrowth in rat cortical neurons [101]. In vivo treatment of
mice with cisplatin signiﬁcantly decreased brain EGT levels and
body weight, increased brain lipid peroxidation (determined viamea-
surement of malondialdehyde using the thiobarbituric acid assay,
which is a rather questionable method [62,124]) and has been sug-
gested to impair cognitive functions in the animals. Supplementation
with EGT via oral gavage, restored levels of EGT in the brain, body
weight and cognitive function and inhibited cisplatin-induced ‘lipid
peroxidation’ [101].
Similar to cisplatin and Aβ, the over-stimulation of N-methyl-D-
aspartate (NMDA) glutamate receptors leads to neuronal cell death
via increased production of free radicals [125]. Intravitreal injection
of NMDA in rats leads to signiﬁcant loss of retinal neurons, however
intraperitoneal injection of EGT signiﬁcantly protected neurons from
NMDA excitotoxicity [126].
5.3. EGT in cardiovascular disease
The immunomodulatory effects of EGT might be beneﬁcial in inhi-
biting the atherogenic induction of pro-inﬂammatory cytokines and
adhesion molecules. Studies in human aortic endothelial cells
revealed that EGT was able to decrease expression of the adhesion
molecules VCAM-1, ICAM-1 and E-selectin and inhibit binding of
monocytes to the endothelium [127]. ROS have been implicated as
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diovascular disorders, however their exact involvement is still uncer-
tain [128]. Evidence for the protective role of EGT against
cardiovascular disease comes from studies of ischemia/reperfusion
(IR), a process involving oxidative stress [62,129]. EGT has been
shown to protect cardiac and liver tissue from damage in vivo during
IR [74,130,131]. The mechanisms by which this protective action is
achieved may be through the previously mentioned (Section 3.1) re-
duction of ferrylmyoglobin protecting tissue from oxidative injury,
evident through decreased tissue malondialdehyde levels and also
through modulation of heat shock protein 70 and proinﬂammatory
cytokines (TNFα and IL-1β) [74,131]. In addition, chelators of iron
and copper have been shown to be protective by decreasing free rad-
ical production during IR, suggesting another mechanism by which
EGT may protect [132–134]. Conﬂicting results were obtained by
Cargnoni and colleagues [135] who failed to see reduction in IR dam-
age in rabbit hearts following administration of EGT ex vivo. Different
methodologies employed by the authors could explain these differ-
ences. The negative result employed an ex vivo model of rabbit
heart IR with the addition of 10 or 100 μM EGT into the perfusion so-
lution only 60 min prior to IR, limiting opportunity for uptake by tis-
sues [135]. The independent studies showing IR protection by EGT,
both utilized rats supplemented with EGT via oral gavage or through
diet, daily for 2 to 3 weeks prior to in vivo liver or intestinal IR injury,
allowing a far greater period of time for uptake and accumulation
[130,131]. The conﬂicting results could also be due to dissimilar ex-
pression of OCTN1 by different animals and tissues (much greater ex-
pression in ileum and liver compared to heart) and hence varying
degrees of uptake and accumulation.
Earlier investigations revealed elevated levels of EGT in diabetic
patients which were suggested to contribute to the onset of diabetes
mellitus through chelation of zinc, which is important for storage of
insulin and glucagon [24,136,137]. However this is unlikely as no sig-
niﬁcant elevation of EGT was observed in alloxan-induced diabetic
rats and studies of metal chelation by EGT have revealed no inhibition
of zinc metalloenzymes [49,138]. On the contrary, in mouse myoblast
cultures, EGT was shown to inhibit palmitic acid-induction of IL-6,
which has been correlated to insulin resistance and type 2 diabetes
[54,139,140]. Furthermore, supplementation of diabetic pregnant
rats with EGT reduced the rate of embryo malformations to that of
non-diabetic controls, which was attributed to modulation of hyper-
glycemia-dependent oxidative stress [141].Fig. 3. Possible roles and interactions of EGT in vivo. Functional roles as an antioxidant are h
blue and roles in disease in orange.6. Conclusions
Many advances in our understanding of EGT have been achieved
in recent years including the identiﬁcation of a highly speciﬁc trans-
porter in higher organisms and humans and also better understand-
ing of its distribution owing to advances in analytical techniques.
Whilst the true physiological role of EGT has yet to be fully elucidated,
EGT has been shown to possess numerous antioxidant and cytopro-
tective effects in vitro and a few in vivo (Fig. 3), including free radical
scavenger activity [57,58,67,72], radioprotective properties [93,94],
anti-inﬂammatory actions [54] and protection against UV radiation
[87–89,142] or neuronal injury [73,101]. The molecular mechanisms
underlying these cytoprotective actions still remain largely
undetermined.
However, despite the wide body of evidence implicating its pro-
tective role, the high levels of EGT identiﬁed in populations suffering
from the chronic inﬂammatory conditions such as RA and CD suggest
it may play a role in the progression of these conditions. Interestingly,
conﬂicting levels of EGT in different subgroups of CD may in part be
due to differing diets or it may highlight other genetic factors which
have yet to be identiﬁed.
Conﬂicting results on antioxidant properties of EGT by various
groups, likely owing to differing experimental conditions and widely
differing concentrations used, often not physiological, have served to
further confuse the role of EGT. Many factors need to be considered
when assessing the result from these assays. Firstly the use of differ-
ent cell types in different studies could also give rise to variations
based on the differences in expression of OCTN1. Studies have
shown that EGT uptake is related to the expression of OCTN1 which
may also limit uptake by some cell types and hence demonstrate a
lower protective effect [46]. Secondly, in many cell culture assays,
the reaction of cellular stressors with EGT may occur outside the
cell giving a false impression of intracellular cytoprotective effects. Fi-
nally, whilst numerous assays demonstrate the unique reactivity of
EGT in vitro, such as scavenging of •OH or ability of “oxidized” EGT
to be regenerated by GSH, it is important to note that these are
often far from the conditions in vivo and hence may not be relevant.
Very few in vivo studies with EGT have been undertaken and this
will need to be addressed further with use of validated biomarkers
of oxidative stress optimized for humans [124,143–147]. Our under-
standing of EGT in the body is still relatively limited and much re-
mains to be learned about this unique compound.ighlighted in yellow, anti-inﬂammatory agent in green, protectant against radiation in
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